Why the study?
Does edoxaban dosing frequency affect intrinsic FXa suppression and bleeding risk in patients from phase 1 and 2 studies?
Does edoxaban dosing frequency affect intrinsic FXa suppression and bleeding risk in patients from phase 1 and 2 studies?
Pharmacokinetic-pharmacodynamic modeling demonstrates that twice-daily edoxaban dosing causes more protracted FXa suppression than once-daily dosing, explaining its higher bleeding risk.
No takes yet. Share an insight, caveat, or question.
Favors once-daily edoxaban to limit bleeding; leaves optimal regimens open pending larger trials.
Song et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: